<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469271</url>
  </required_header>
  <id_info>
    <org_study_id>17-009440</org_study_id>
    <nct_id>NCT03469271</nct_id>
  </id_info>
  <brief_title>Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients</brief_title>
  <official_title>Resistance Training and 1,25 (OH)2D3 Administration to Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Andersen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is intended to begin to explore the impact of inspiratory muscle resistance
      exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients
      (subjects).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">April 2, 2018</start_date>
  <completion_date type="Anticipated">May 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sniff Nasal Inspiratory Pressure (SNIP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>SNIP is a test of maximal inspiratory muscle force exerting from the diaphram. Patients sniff forcefully through one nostril while the other is obstructed. The best of 10 measurements is recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence Questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>The questionnaire consists of one question with 5 choices about how often did the participant take the study agent: all the time, most of the time, half of the time only some of the time, and none of the time. Scores will be reported as categories.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Training and Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Training and Vitamin D3 Metabolite</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training and Vitamin D3 Metabolite</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Training and Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1,25 (OH)2 D3</intervention_name>
    <description>0.25 micrograms, taken daily for eight weeks, orally</description>
    <arm_group_label>Sham Training and Vitamin D3 Metabolite</arm_group_label>
    <arm_group_label>Training and Vitamin D3 Metabolite</arm_group_label>
    <other_name>Calcitriol</other_name>
    <other_name>1, 25-dihydroxycholecalciferol</other_name>
    <other_name>Rocaltrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inspiratory isometric resistance training</intervention_name>
    <description>A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).</description>
    <arm_group_label>Training and Placebo</arm_group_label>
    <arm_group_label>Training and Vitamin D3 Metabolite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>Placebo will be created to mimic the appearance of the study drug</description>
    <arm_group_label>Training and Placebo</arm_group_label>
    <arm_group_label>Sham Training and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Inspiratory Isometric Resistance Training</intervention_name>
    <description>A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.</description>
    <arm_group_label>Sham Training and Vitamin D3 Metabolite</arm_group_label>
    <arm_group_label>Sham Training and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Threshold Inspiratory Muscle Trainer (IMT)</intervention_name>
    <description>A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.</description>
    <arm_group_label>Training and Placebo</arm_group_label>
    <arm_group_label>Sham Training and Vitamin D3 Metabolite</arm_group_label>
    <arm_group_label>Training and Vitamin D3 Metabolite</arm_group_label>
    <arm_group_label>Sham Training and Placebo</arm_group_label>
    <other_name>Threshold IMT Breathing Trainer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cancer

          -  Renal and hepatic function (creatinine &lt;/= 2 x the institutional upper limit of
             normal; bilirubin &lt;/= 2 x the institutional upper limit of normal)

          -  No contraindication to receive either of the planned interventions of inspiratory
             resistance training or 1,25(OH)2D3 in the opinion of the healthcare provider

          -  No difficulties with swallowing oral medications in the opinion of the enrolling
             physician

        Exclusion Criteria:

          -  Patient is taking calcium or Vitamin D supplements and is unwilling to stop for 8
             weeks

          -  Severe chronic obstructive pulmonary disease (oxygen dependent or patient self-reports
             unable to walk one block without difficulty)

          -  Calcium or phosphorus level above the institutional upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminah Jatoi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Aminah Jatoi, M.D.</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

